Pancreatic Cancer

Standard eligibility criteria for pancreatic cancer clinical trials differentially exclude Black patients from participation, according to results a simulated screening process.

The FDA granted orphan drug designation to nadunolimab for the treatment of pancreatic cancer.

In this episode, Kevin C. Soares, MD, discusses his path to GI oncology, how immune therapy complements surgical interventions, and shares his thoughts on how the pandemic will impact medical practices.

The FDA granted orphan drug designation to LP-184 for the treatment of pancreatic cancer.

For patients with recurrent and metastatic pancreatic cancer who received chemotherapy as a first-line treatment, early tumor shrinkage correlated with an improved rate of progression-free survival and overall survival.

An electronic, odor-based tool accurately distinguished pancreatic and ovarian cancer specimens from benign disease and control specimens by analyzing vapors emanating from blood samples, according to results of a small, preliminary study.

In this video exclusive, Roi Anteby, MD, postdoctoral research fellow, department of surgery, Massachusetts General Hospital, discussed the affect of race, socioeconomic status and education on completion of adjuvant therapy for pancreatic cancer.

Although patients in underrepresented groups present with worse outcomes than white patients, pancreatic cancer trials fail to represent non-white patients, according to a presentation at Digestive Diseases Week.

Maintenance rucaparib appeared safe and effective for patients with platinum-sensitive advanced pancreatic cancer with pathogenic variants in BRCA1, BRCA2 or PALB2, according to research published in Journal of Clinical Oncology.

The diagnostic yield of pancreatic ductal adenocarcinoma was substantial in high-risk mutation carrier but non-existent in mutation-negative proven familial pancreatic cancer kindreds.